Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TLR 7 was expressed in all cancer specimens, but elevated expression was evident in HPV and/or p16-positive tumors.
|
25941114 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TLR 7 was expressed in all cancer specimens, but elevated expression was evident in HPV and/or p16-positive tumors.
|
25941114 |
2015 |
Pancreatic carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
TLR7 has previously been demonstrated to be associated with the development of pancreatic cancer, and the release of cytokines and chemokines from other types of cancer cell; however, the specific expression induced by TLR7 agonists in pancreatic cancer cells remains to be elucidated.
|
26718740 |
2016 |
Malignant neoplasm of pancreas
|
0.070 |
Biomarker
|
disease |
BEFREE |
TLR7 has previously been demonstrated to be associated with the development of pancreatic cancer, and the release of cytokines and chemokines from other types of cancer cell; however, the specific expression induced by TLR7 agonists in pancreatic cancer cells remains to be elucidated.
|
26718740 |
2016 |
Ischemic stroke
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TLR7 mRNA expression of the IS cases was statistically significantly higher than that of the controls in the male or female group (male, P = 0.014; female, P = 0.025).
|
27427388 |
2016 |
HIV-1 infection
|
0.040 |
Biomarker
|
disease |
BEFREE |
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
|
27799218 |
2017 |
Primary Sjögren's syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
TLR7 and 8 are encoded by genes localized on the X chromosome, which is especially interesting regarding the gender imbalance of pSS.
|
27943374 |
2017 |
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
TLR7 expressions of the good outcome group increased within 3 days following stroke onset.
|
28017496 |
2017 |
Jones syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TLR7 mRNA levels in rCDs were also significantly elevated in comparison to the CD-GFD patients (2.11 times higher; p < 0.01).
|
28028951 |
2017 |
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR7/9 signals are capable of mounting massive interferon (IFN) response in plasmacytoid dendritic cells (pDCs) immediately after viral infection, yet the involvement of epigenetic regulation in this process has not been documented.
|
28416650 |
2017 |
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 7 (TLR7) is associated with the pathophysiology of systemic lupus erythematosus and Sjögren syndrome, well-known diseases accompanying interstitial cystitis (IC).
|
28595240 |
2017 |
Sjogren's Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 7 (TLR7) is associated with the pathophysiology of systemic lupus erythematosus and Sjögren syndrome, well-known diseases accompanying interstitial cystitis (IC).
|
28595240 |
2017 |
Interstitial Cystitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 7 (TLR7) is associated with the pathophysiology of systemic lupus erythematosus and Sjögren syndrome, well-known diseases accompanying interstitial cystitis (IC).
|
28595240 |
2017 |
Infective cystitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor 7 was up-regulated in the bladder mucosa of patients with HIC, and activation of TLR7 in the mouse bladder induced cystitis with sensory hyperactivity of the bladder.
|
28595240 |
2017 |
Hyperactive behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Toll-like receptor 7 was up-regulated in the bladder mucosa of patients with HIC, and activation of TLR7 in the mouse bladder induced cystitis with sensory hyperactivity of the bladder.
|
28595240 |
2017 |
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR7 can be triggered not only by ssRNA during viral infections, but also by immune modifiers that share a similar structure to nucleosides.
|
28620298 |
2017 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy.
|
28652396 |
2017 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Toll-Like Receptor 7 Staining in Malignant Epithelial Tumors.
|
28857981 |
2017 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
|
29378197 |
2018 |
Skin lesion
|
0.010 |
Biomarker
|
group |
BEFREE |
TLR-7 agonists are successfully used as topical treatment for various (pre)malignant skin lesions and are now under investigation as intravesical therapy for non-muscle-invasive bladder cancer.
|
29500135 |
2018 |
Carcinoma of urinary bladder, invasive
|
0.020 |
Biomarker
|
disease |
BEFREE |
TLR-7 agonists are successfully used as topical treatment for various (pre)malignant skin lesions and are now under investigation as intravesical therapy for non-muscle-invasive bladder cancer.
|
29500135 |
2018 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Toll-like receptor 7 (TLR7) is an important molecule involved in the development of autoimmunity and the response to different pathogens.
|
29599669 |
2018 |
Polyendocrinopathies, Autoimmune
|
0.030 |
Biomarker
|
group |
BEFREE |
TLR7 stimulation induced a general downregulation of miRNAs, similar to the pattern observed in SLE and APS patients. miR-361-5p, miR-128-3p and miR-181a-2-3p expression was lower in patients with a high IFN signature (false discovery rate <0.05) as compared with patients with a low IFN signature and HCs.
|
29873766 |
2018 |
Influenza A
|
0.060 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 7 (TLR-7) and melanoma differentiation-associated protein 5 (MDA5) receptors showed decreased expression in influenza A infected MK1-OSU cells, while only TLR-7 expression decreased in SD-PJEC cells.
|
29880757 |
2018 |
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
TLR7 activation is an important contributor to systemic lupus erythematosus pathogenesis, but the mechanisms by which type I IFNs participate in TLR7-driven pathologic conditions remain uncertain.
|
29884703 |
2018 |